Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Vibrio cholerae Inaba 6973 El Tor biotype, formalin inactivated
- Development stage
- Unknown
- Lead developer
- EuBiologics
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Oral
01
Overview
Vibrio cholerae Inaba 6973 El Tor biotype, formalin inactivated is an oral vaccine containing whole cells of the V. cholerae O1 serogroup (specifically the Inaba Phil 6973 El Tor strain) that have been rendered non-infectious by treatment with formaldehyde. It is used for active immunization against cholera caused by Vibrio cholerae O1 and is typically administered as part of a multi-strain formulation alongside other V. cholerae strains such as Ogawa Cairo 50 and sometimes O139. The vaccine works by stimulating mucosal and systemic immune responses to key surface antigens of the bacterium, providing protection against infection and disease[4][5][8]. Formalin-inactivation preserves important heat-sensitive antigens like mannose-sensitive hemagglutinin (MSHA), enhancing immunogenicity compared to phenol-inactivated vaccines[5][6]. The primary indication is prevention of epidemic or endemic cholera; efficacy has been demonstrated for both outbreak control and routine immunization programs[4][8].
- Brand names
- Euvichol-S Cholvax
- Other names
- V. cholerae O1 Inaba Phil 6973 El Torformaldehyde inactivated Vibrio cholerae O1 Inaba 6973 El Tor biotype, formalin-inactivated
02
Targets
V. cholerae O1 LPS (Vibrio cholerae O1 lipopolysaccharide)
Beyond the preview
Go deeper on Vibrio cholerae Inaba 6973 El Tor biotype, formalin inactivated.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vibrio cholerae Inaba 6973 El Tor biotype, formalin inactivated.